Ncardia

Ncardia is a stem cell technology company focused on the cell therapy, drug discovery, and safety/tox markets. We believe that human stem cell biology will deliver superior therapies to patients faster by improving the drug discovery & development process. We work with clients to develop human disease models and optimized assay systems to enable safety and efficacy testing that better translate to the clinic. Our novel DiscoverHIT Screening Platform offers a flexible solution for bringing human induced pluripotent stem cell (hiPSC) models to drug discovery campaigns, while our robust Manufacturing Platform allows liter-scale batches of high quality, functional cells with little batch to batch variation. For post-manufacturing analysis,  Ncardia has an extensive selection of instrumentation and in-house technologies for identity verification as well as extensive functional characterization. Ncardia cells are ideally suited, then, for drug screening efforts as well as cell therapy projects.

Whitepaper: Advancing drug discovery for neurodegenerative diseases

Whitepaper: Advancing cardiac drug discovery with iPSC technology

Whitepaper: How to successfully use iPSCs for disease modelling

Application note: Validation of identified through AI

Case study: Parkinson’s disease modelling for drug discovery

Whitepaper: Automated cell culture and screening

Interview: Stefan Braam, CEO & Founder of Ncardia

Whitepaper: Neuroinflammation study

Whitepaper: iPSC manufacturing for drug discovery

Right model, right complexity: using in vitro human disease cell models in drug discovery

Targeting tau – chasing a treatment for Alzheimer’s

Drug Target Review Neuroscience ebook 2022

Chiral nanostructures could help accelerate drug discovery

Miniaturising organoid drug screens using nanofibrillar cellulose hydrogels

Drug Target Review Screening ebook

The Crick HTS facility – facilitating research through large-scale screening

High-throughput screening as a method for discovering new drugs

If Columbus had a map… guiding the discovery of new drugs

Current state of NAFLD treatments and the promise of in vitro platforms towards better screening of drug candidates

Expert view: Finding a translatable disease model suitable for drug discovery screening

Screening In-Depth Focus 2020

Human iPSC-derived functional cells are revolutionising phenotypic drug discovery and development

Cellistic and Celyad Oncology announce GMP cell therapy manufacturing operations transaction

Ncardia appoints Andy Holt as Chief Commercial Officer

Ncardia secures more than $60 million to enhance and expand leading iPSC offerings

Video: Ncardia’s iPSC technology

Phenotypic screening using iPSC-based human disease biology